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Objective. To review the management and outcomes of women with surgically staged 1 UPSC. Methods. We report on a case
series from 2008–2010 from Hamilton Canada. We summarize the data from a literature search on surgically staged 1 UPSC.
Results. There is a group women with Stage 1A UPSC with no residual disease at time of surgery who do not require adjuvant
therapy. Vault recurrences appear to be lower in women who received adjuvant vault radiation. Chemotherapy appears to confer
longer survival for those women with Stage 1B or 1C disease compared of those observed or who had radiation alone. Conclusion.
Adjuvant therapy appears to confer beneﬁt in certain groups of women with stage 1 UPSC. A randomized controlled study would
clarify the degree of beneﬁt.
1.Background
Karpas ﬁrst described an endometrial cancer with psammo-
matous bodies in 1963 [1]. Uterine papillary serous cancer
(UPSC) was described as a distinct entity by Lauchlan in
1981[2].HendricksnoticedthatalthoughUPSCrepresented
4% of all uterine cancers; it accounted for 50% of the
uterine cancer recurrences [2–10]. In fact, early stage UPSC
accounted for 25% of deaths from uterine cancer [2–4, 11–
23]. The poor prognosis of UPSC was explained in part due
to the unrecognized presence of metastatic disease at initial
presentation. Goﬀ showed that 72% of women with clinical
Stage 1 UPSC had extrauterine disease at the time of surgery
in comparison to a rate of 25% in women with endometrioid
cancer. In Goﬀ’s study, the retroperitoneal nodes were posi-
tive in 36% of women without invasive disease, 50% with
inner half myometrial involvement and 40% with outer
half myometrial involvement. Peritoneal disease was seen in
43%, 37%, and 35%, respectively [24–29]. More recently,
it was noted that even surgically staged patients, who had
Stage 1 UPSC, had a propensity to develop recurrent disease
[30, 31]. If women with surgically staged early disease
have poor outcomes, the next questions are whether there
is any adjuvant treatment that could either improve or
prolong duration of survival. Our objective in this paper
was to document the 2-year survival and recurrence rate of
women with surgically staged 1 UPSC treated with adjuvant
chemotherapyand/orradiationtherapy.Asnoonecentrehas
many cases, we planned to review the literature to see if any
themes arose.
2. Methods
2.1. Case Series. In 2009, our disease site team reviewed the
literature and subsequently changed out treatment policy for
womenwithStage1UPSC.Wemovedfromobservationonly
to oﬀering the sandwich technique of 3 cycles of carboplatin
followedbybrachytherapyandthen3furthercyclesofcarbo-
platin.WomenwithUPSCwereidentiﬁedbythreestrategies:
the pathology database at Hamilton Health Sciences Centre
(this includes all surgical cases done on site and all pathology
consults from the local health integrated network), the
cancer centre database (this includes all new patient referrals
to the cancer centre), and a review of all weekly gynaecologic
oncology tumour board meeting minutes from 2008 to2 ISRN Obstetrics and Gynecology
present. The search terms included serous uterine cancer and
UPSC. The charts of all cases were reviewed. FIGO staging
was according to the 1988 classiﬁcation. Only women who
were Stage 1 by surgically staging with washings, hysterec-
tomy, bilateral salpingoophorectomy, omentectomy, and re-
troperitoneal node dissection were included.
Disease characteristics included depth of invasion,
amount of serous component and lymphovascular space in-
volvement. Amount of serous component was deﬁned as
pure if the specimen contained at least 90% serous cancer
and mixed if it did not.
Management included chemotherapy with platinum
taxaneusuallywithcarboplatinAUC5basedon24collection
of urinary creatinine clearance and a 3-hour infusion of pa-
clitaxel 175mg/m2 q3 weeks. Radiation involved either vault
brachytherapy to a dose of 1050cGy and/or whole pelvis
radiation to 4500cGy.
2.2. Literature Review. Search strategy included MEDLINE
(1980–2011), EMBASE (1980–2011) and the Cochrane
Library databases for systematic reviews and clinical trials.
Reference lists of papers and review articles were scanned
for additional citations. Abstracts from 1997 to 2011 annual
meetings of the American Society of Clinical Oncology
(ASCO) were also searched. Canadian Medical Associate
(CMA) Infobase (https://mdm.ca/cpgsnew/cpgs/search/
english/help/help-glossary.html), the National Guidelines
Clearinghouse (http://www.guideline.gov/), and other web
sites were searched for existing evidence-based practice
guide-lines. Search terms related to study design, used to
search the MEDLINE and EMBASE databases, included
case series, cohort studies, clinical trials meta-analysis and
systematic review. The following test words and medical
subjecthead-ings(MeSH)wereusedtoidentifytheliterature
regard-ing adjuvant therapy in women with serous cancer of
theuterine:uterinepapillaryserouscarcinoma,drugtherapy,
chemotherapy, and radiation therapy. To be included in this
paper, patient could have pure or mixed UPSC, all women
were surgicallystaged Stage 1 disease, or the authorindicated
that the rate of surgically staging was 80% or higher and
the study is about this population or we are able to pull out
speciﬁcpatientsfromthedetailsinthepatientsthatweresur-
gically staged and their adjuvant management and outcomes
information were clearly deﬁned.
3. Results
3.1. Case Series. We report on 26 Stage 1 UPSC cases who
underwent surgery. Five are excluded as they did not have
retroperitoneal node dissection. There were 6 women with
Stage 1A disease. All patients had residual tumour in the
uterus at the ﬁnal pathology. There were 10 women with
Stage 1B and 5 women with Stage 1C diseases.
In those with Stage 1A disease, only 1 patient received
the recommended treatment, 2 only received chemotherapy
and, 3 received no treatment. In those with Stage 1B disease,
5 received carboplatin and paclitaxel plus brachytherapy, 1
received carboplatin and paclitaxel, alone and 4 received
no treatment. In those with Stage 1C disease, 3 received
carboplatin with brachytherapy, 1 received carboplatin with
pelvic radiation, 1 received carboplatin alone, and 1 had no
treatment. There were 2/9 cases of treatment delay due to
neutropeniainthegroupwiththesandwichtechnique.There
were 2/4 cases of treatment delay due to thrombocytopenia
in the chemotherapy-only group. Our disease site team had a
50% compliance with the guideline.
All patients are alive at a median of 16-month followup
(range 4–40, mean 16.4 mos). There were 2 recurrences at 12
and 13 months of followup. Both were vaginal recurrences in
patientswithStage1Cdisease.Inbothcases,thepatientshad
not received upfront radiation therapy.
3.2. Literature Search Results. There was one prospective
Phase 2 study addressing feasibility and toxicity of the sand-
wich technique of 3 cycles of chemotherapy then radiation
and 3 further cycles of chemotherapy [32]. 16 retrospective
studies reported survival and recurrence outcomes for
womenwithsurgicallystagedStage1UPSC.9studiesfocused
on Stage 1 disease [22, 29, 33–41]. The other 8 studies dis-
cussed all stages [28, 32, 42–47] but with enough informa-
tion so that the Stage 1 patients could be identiﬁed and their
outcomes were available.
3.3. Management. Most of the women in these studies began
their management with surgical staging. Surgical staging
involved hysterectomy, bilateral salpingoophorectomy, as
well as retroperitoneal node dissection, omentectomy, and
washings with or without peritoneal biopsies. The impor-
tance of surgical staging has been identiﬁed by several
authors. Unlike endometrioid uterine cancer, in UPSC,
metastatic disease cannot be reliably predicted based on
uterine factors as women with apparent early disease (i.e.,
involving a polyp) may have already widespread intra-abdo-
minal metastases. Thomas et al. [41] showed that 30% of
women without clinical evidence of extrauterine disease at
surgery were upstaged by the routine biopsies. Thomas et al.
[41] in his series noted a clear shift in their practice in 1995
to surgically staging women with UPSC patients (i.e., at least
a pelvic node dissection).
In 12 studies, women received just adjuvant chemother-
apy.In13studies,thewomenreceivedsomeformofadjuvant
radiation: (a) vault radiation, (b) pelvic radiation, (c) whole
abdominal pelvic radiation (WART), or (d) a combination
of radiation techniques. In 8 studies, women received a
combination of chemotherapy and one or more radiation
techniques.
Thereisaclearbiasintheretrospectivestudiestoprovide
women with deeper myometrial involvement with adjuvant
therapy. For example, in Elit et al. [35], 86% of women with
Stage 1A disease received no adjuvant therapy, whereas 88%
withStage1Cdiseasereceivedadjuvanttherapy.Conclusions
about adjuvant therapy may be diﬃcult to draw based
on this bias. However, reviewing case series can help us
identify some themes that would deﬁne future directions.
For example, do all patients require adjuvant therapy? If
there is a speciﬁc group of women such as those with noISRN Obstetrics and Gynecology 3
myometrial involvement (i.e., Stage 1A) that has excellent
outcomeswithoutadjuvanttherapy,thiswouldbeimportant
to know. If, however, all patients had poor outcomes, an
argument could be made not to do extensive surgical staging
and just provide adjuvant therapy.
Table 1 shows the surgical staging and histology infor-
mation of the surgically staged patients included in this
study. Table 2 shows the risk of recurrent disease. Certainly,
there appears to be a gradient of increase risk of recurrent
disease as myometrial invasion increases from Stage 1A to
1C. The numbers are low, but serous versus mixed tumours
and presence or absence of lymphovascular invasion do not
appear to predict recurrence.
Table 3 shows the information on diﬀerent patterns of
adjuvant therapy. Certainly, the only group with signiﬁcant
number are the women who had surgical staging and were
observed. Table 4 deﬁnes the recurrence rate by adjuvant
treatment and stage.
Looking at the observation group alone, there is a sub-
stantial diﬀerence in recurrence rates between those with
Stage 1A and the other Stages 1B-1C.
Looking at the individual studies, some authors have advo-
cated observation only after surgical staging and disease truly
limited to the uterus [22, 28, 29, 33, 35–44, 46, 47]. Others
like Kelly et al. [40] showed that the greater the myometrial
invasion, the more likely a recurrence is seen with obser-
vationalone(43%Stage1Arecurred,77%Stage1Brecurred,
80% Stage 1C recurred). There does appear to be a gradient
in risk of recurrence by Stages 1A,B,C. When focusing on
Stage 1A UPSC, some authors showed no risk of relapse
[22, 32] or a low risk of relapse up to 12% [27, 43, 48–
50]. Works by Hui et al. [51] and Kelly et al. [40]h a v e
shown no recurrences in women observed with Stage 1A
disease without residual UPSC, this is in contrast to a 43%
recurrence rate for Stage 1A patients with residual uterine
disease in the hysterectomy specimen who were observed.
Thus, they suggest no adjuvant therapy for just those women
with no residual uterine disease at time of deﬁnitive surgical
staging.
Lookingatwhetherradiationimprovedsurvivaloverand
above observation alone, the only group that appeared to
beneﬁt was the Stage 1B population. The individual studies
addressedvariousformsofradiationtherapy.Vaultradiation
hasbeenusedtodecreasevaginalrelapse.Pelvicradiationhas
been used to decrease locoregional recurrence. Whole abdo-
minal pelvic radiation therapy has been used to sterilize the
whole abdominal cavity (WART).
Huh et al. [29] and Kelly et al. [40] showed that if pa-
tients with surgical Stage 1 disease were not treated with
pelvic or vault radiation, there was a 10–19% chance of re-
curring at the vaginal vault. The risk of vault recurrence
appears to be related to depth of myometrial invasion. There
was a 29% rate of vault recurrence in women with Stage
1B and 1C diseases in absence of adjuvant RT [41]. Vault
radiation appears to decrease recurrences as compared to no
adjuvant therapy. Kelly reported a vaginal recurrence rate
of 19% (6/13) in Stage 1 UPSC in absence of adjuvant RT
versus none in the 43 women who received RT (VB = 38,
pelvic RT = 5). Use of WART in UPSC was ﬁrst reported
by Frank et al. [52] and others [53, 54]. The earlier studies
suggested a beneﬁt from WART in patients with Stage 1–3
disease. It was diﬃcult to comment on outcomes of WART
in Stage 1 disease given the information available. The results
from adjuvant radiation alone still result in a high distant
recurrence rate.
Looking at chemotherapy alone, again the numbers per
strata are small, but there is a trend to markedly lower re-
currences across the Stages 1A to 1C compared to obser-
vation alone or radiation. Several chemotherapy agents have
been used alone or in combination for this disease. The most
common agents used either alone or in combination include
platinum, taxane, doxorubicin, and cyclophosphamide [8,
30, 55, 56]. In the individual studies, Fader et al. [37, 38]
showed that those 89 patients who had chemotherapy had a
superior OS and PFS (81.5% and 87.6%) compared to those
33 women observed (64.7% and 70.2%) and the 20 women
treated with radiation (64.1% and 59.5%). On multivariate
analysis, only chemotherapy signiﬁcantly and favourably
impacted upon recurrence rates and PFS (P = 0.006). Age
(P = 0.05), stage (P = 0.05), and chemotherapy (P = 0.02)
were associated with over-all survival [38]. Kelly et al. [40]
showed that in those Stage 1A patients given chemotherapy
there were no recurrence compared to 43% recurrence in
those not given chemo. In Stage 1B patients treated with
chemotherapy, there were no recurrences compared to 77%
inthosenottreat-edwithchemotherapy.InStage1Cpatients
treated with chemotherapy, there were no recurrences com-
pared to 80% in those not treated with chemotherapy. Over-
all, you had a 100% chance at survival with chemotherapy
com-pared to 46% without chemotherapy. Dietrich et al.
[34] showed in a multi-institutional retrospective study that
all 21 surgically staged 1 patients treated with 3–6 cycles
of carboplatin taxane were alive and well at a minimum
of 8mos. One had developed a vaginal recurrence that was
managed with radiation. In 8 patients treated with other pla-
tinum single agent or combinations, 10-year survival was
only 85% with 2 recurrences, 1 distant disease who died at
24mos and 1 vaginal recurrence still alive after retreatment
with chemotherapy and radiation. Huh et al. [29] showed
no recurrences in the 7 patients treated with platinum-
based chemotherapy. Fader et al. [38] showed that those
with chemotherapy had a reduction in recurrences (11.2%)
com-pared to those who did not have chemotherapy (28.3%,
P = 0.013). PFS for CT-treated patients was statistically
signiﬁcantly higher than for those who did not receive CT
(P = 0.013). CT with or without RT was associated with
improved PFS compared with treatment with RT also or
observation (P = 0.027). This was most pronounced for
Stage 1B patients. Overall survival did not reach statistical
signiﬁcance.
The problem with chemotherapy alone was a concern for
the high rate of recurrences especially at the vaginal apex.
Looking at that chemotherapy and radiation data, the cell
sizes are larger than the chemotherapy alone data. How-
ever, the rate of recurrences by substage look similar to
the chemotherapy alone data and much better than the ob-
servation alone data. The individual studies on sequential or4 ISRN Obstetrics and Gynecology
Table 1: Characteristics of the Stage 1 UPSC studies included in this paper.
Author Publication year Single- or multi-institutional Time period Number of Stage 1 patients Median FUP mos
Bancher-Todesca et al. [42] 1998 Multi 1988–1995 3 36
Bristow et al. [28] 2001 Single 1989–1998 11 46
Carcangiu et al. [33] 1997 Multi 1987–1995 13 38
Dietrich et al. [34] 2005 Multi 1990–2003 29 31
Elit et al. [35] 2004 Multi 1985–2001 43 40
Fader et al. [36–38] 2009 Multi 1993–2006 142 37
Fields et al. [32] 2008 Single 1999–2004 16 50
Gallion et al. [22] 1989 Single 1973–1987 11 NR
Gehrig [44] 2001 Single 1990–2000 6 24
Grice et al. [43] 1998 Single 1982–1993 12 43
Huh et al. [29] 2003 Multi 1987–2000 60 30
Havrilesky et al. [39] 2007 Multi 1976–2006 83 NR
Kelly et al. [40] 2005 Single 1987–2004 74 NR
Low et al. [45] 2005 Single 1994–2003 9 28
Piura et al. [46] 1998 Multi 1991–1997 7 35
Slomovitz et al. [47] 2003 Single 1989–2002 52 NR
Thomas et al. [41] 2007 Single 1982–2005 42 39 8
Elit et al.∗ 2011 Single 2008–2011 21 16
TOTAL 613
∗Data from Elit are not added to summary statistics as median followup is less than 24 months.
concurrent chemoradiation also suggest beneﬁt [10, 40, 57].
Havrilesky et al. [39] showed that the 3yr OS and PFS for
chemo (92%, 76%) or chemo with radiation (89%, 77%)
were superior to observation (80%, 78%) or radiation alone
(63%, 44%). Fader et al. [38] showed that chemoradiation
providedasuperiorrecurrenceoutcomethanradiationalone
(P = 0.027). Turner showed a superior 5yr OS in the women
receiving chemotherapy and vault RT (94%) compared to
those treated with WART + vault RT (65%). Rosenburg et al.
[8]o ﬀered 8 Stage 1 patients chemotherapy and radiation
and there were no recurrences at 32 mos. Bancher-Todesca
et al. [42] treated 4 Stage 1 patients with platinum and pelvic
radiation and they are all alive at 39mos. Low et al. [45]r e -
ported on 9 Stage 1 patients being treated with 4 cycles of
platinum followed by pelvic radiation and in 5 cancer vault
brachytherapy. There was 1 recurrence.
A novel chemoradiation approach dubbed the “sandwich
technique” was evaluated by Fields et al. [32]. He conducted
a prospective pilot study to assess the feasibility of 3 courses
of chemotherapy, then pelvic radiation therapy followed by
3 further cycles of chemotherapy. Patients could have had
any stage of UPSC. The treatment was tolerable with 97%
of patients completing the intended treatment. 42% for the
cycles were associated with grade 3/4 neutropenia and only
3% needed a one-week treatment delay. There were no cases
of febrile morbidity.
4. Discussion
We have pooled the data across various-case series in surgi-
cally staged women with Stage 1 UPSC. We show that the re-
currence rates of those observed is signiﬁcantly diﬀerent
in those with Stages 1B and 1C compared to those with
Stage 1A disease. We show that recurrence rates are im-
proved especially in those with Stage 1B and 1C diseases
who receive adjuvant therapy including chemotherapy. To
minimize vault recurrence, the addition of at least vault bra-
chytherapy has been recommended. Our small case series
reinforcesthisissue.However,thestratasizesinthisstudyare
too small to make this conclusion strongly. Although there is
agreement to oﬀer adjuvant treatment to women with Stage
1B and 1C diseases, the evidence is not as compelling as
for the adjuvant treatment of those with Stage 1A disease.
There appears to be a subgroup of Stage 1A patients without
residual disease in the hysterectomy specimen which has a
low chance of recurrence in whom observation seems appro-
priate.
There are signiﬁcant limitations of this paper. We use the
1988 FIGO staging system in order to compare studies using
the same staging classiﬁcation. Given the new 1998 FIGO
staging system, the old Stages 1A and 1B will be collapsed
into Stage 1A. The old Stage 2A will now be absorbed with-
in Stage 1. The subtleties of management and outcomes
using the old staging system will be lost when categoriz-
ing patients with new system. The plethora of small case
series exist because of the relative rarity of surgically staged
1 UPSC cases. Some of the issues that exist in trying to
compare these studies include that many studies involved
single versus multiple centres. Data collection in multicentre
studies is more likely to be stringent as a data dictionary
would have been used to deﬁne and collect similar data.
Most of the studies are retrospective with the exception of
prospective study by Fields. Thus, there is a strong risk of
bias for treatment as we saw for the women with StagesISRN Obstetrics and Gynecology 5
Table 2: Disease characteristics of the patients in these studies.
Author Stage (numbers) Serous Mixed LVI (percent of cases)
1A 1B 1C Total + − Unknown
Bancher-Todesca et
al. [42] 1113 — — ———
Bristow et al. [28]4 7—1 0——— — —
Carcangiu et al. [33] 1 3——1 3—— — — —
Dietrich et al. [34]7 1 7 5 2 91 6 5 — — —
Elit et al. [35]2 2 1 3 8 4 3 36
83%
7
17% ———
Fader et al. [36–38] 51 65 26 142 — — — — —
Fields et al. [32]2 1 2 2 1 6 — — — — —
Gallion et al. [22]3 5 31 1 — — 7
64%
4
36% —
Gehrig [44]6 — — 6 — — 5
83%
1
17% —
Grice et al. [43]4 4 4 1 2 — — — — —
Huh et al. [29] 1 92 61 56 051
85%
10
15% ———
Havrilesky et al. [39] 3 23 41 68 2—— 18
22%
54
65%
11
13%
Kelly et al. [40] 3 32 91 27 447
64%
27
36% ———
Low et al. [45]1 6 2 9 — — — — —
Piura et al. [46]1 3 3 7 — — — — —
Slomovitz et al. [47]1 9 2 6 7 5 2 27
56%
23
44%
12
23%
40
77% —
Thomas et al. [41]1 5 2 1 6 4 2 — — — — —
Elit et al.∗ 61 052 1 19
90%
2
10%
3
14%
18
86% —
TOTAL 233 269 110 611 177/258
69%
72/258
28%
42/151
28%
99/151
66%
11/82
13%
∗Data from Elit are not added to summary statistics as median followup is less than 24 months.
Table 3: Disease recurrences by disease characteristic.
Author Stage Serous Mixed LVI
1A 1B 1C + − Unknown
Bancher-Todesca et al. [42] 0/1 0/1 0/1 — — — — —
Bristow et al. [28]1 / 4 1 / 7 — — — — — —
Carcangiu et al. [33]2 / 1 3—— — — — — —
Dietrich et al. [34] 0/7 2/17 1/5 3/16 0/5 — — —
Fader et al. [36–38] 6/51 11/65 8/26 — — — — —
Fields et al. [32] 0 3/12 2/2 — — — — —
Gallion et al. [22] 0/3 4/5 1/3 — — 5/7 0 —
Gehrig [44]2 / 6 — — — — — — —
Grice et al. [43] 0/4 0/4 2/4 — — — — —
Havrilesky et al. [39] — — — — — 18 53 11
Kelly et al. [40] 6/33 6/29 8/12 — — — — —
Low et al. [45] 0/1 1/6 0/2 — — — — —
Piura et al. [46] 0/1 0/3 1DOC/3 — — — — —
Slomovitz et al. [47]4 / 1 9—— — — — — —
Elit et al.∗ 0/6 0/10 2/5 2/19 0/2 1/3 1/18
21/143 (15%) 31/149 (21%) 22/56 (39%) 19% 0 22% 65% 13%
∗Data from Elit are not added to summary statistics as median followup is less than 24 months.6 ISRN Obstetrics and Gynecology
Table 4: Description of management.
Author Observe RT CT CT 3CT-RT-3CT
Vault Pelvic Pelvic + Brachy WART Other Brachy
Bancher-Todesca et al. [42]2 — — 1 — —— — —
Bristow et al. [28]1 0 1 — — — — — — —
Carcangiu et al. [33]1 — — —2 — — 1 0 —
Dietrich et al. [34]— — — — — — 2 8 — —
Elit et al. [35]2 7 — 4 — 6 — 6 — —
Fader et al. [36–38] 33 — — — — 20 — 89CT with or without RT —
Fields et al. [32]— — — — — — — — 1 6
Gallion et al. [22]5 — — 6 — — —— —
Gehrig [44]6 — — — — — — — —
Grice et al. [43]5 — 4 2 1 — — — —
Huh et al. [29]4 0 4 — 5 3 — 7 — —
Havrilesky et al. [39]4 7 7 1 0 4 9 — 1 7 — —
Kelly et al. [40]1 1 3 — — 1 — 2 1 8 —
Low et al. [45]— — — — — — — 9 —
Piura et al. [46]3 — — 3 — — 1 3 —
Slomovitz et al. [47]2 7 6 2—3 — 5 1 —
Thomas et al. [41]1 7 9 6 — 3 — 2 5 —
Elit et al.∗ 8— — — — — 4 — 9
234 30 26 21 28 20 87 125 16
∗Data from Elit are not added to summary statistics as median followup is less than 24 months.
Table 5: Recurrence rate by adjuvant treatment and stage of disease.
Author Observation Radiation Chemotherapy CT+RT
1A 1B 1C 1A 1B 1C 1A 1B 1C 1A 1B 1C
Bancher-Todesca et al. [42]0 / 1 0/1 0/1
Bristow et al. [28]1 / 4 1/1
Carcangiu et al. [33] 0/1 1/ 2 1/10
Dietrich et al. [34] 0/7 2/17 1/5
Elit et al. [35] 2/19 3/7 0/1 0/5 3/5
Fader et al. [36–38] 3/19 4/9 3/5 1/5 2/9 2/6 2/27 5/47 3/15
Fields et al. [32] 0/2 3/12 2/2
Gallion et al. [22]0 / 3 0 / 1 1/1 0/0 4/4 1/2
Gehrig [44]2 / 6
Huh et al. [29]1 / 3 0/6 1 /3 0/2 0/3 0/2 0/1
Low et al. [45] 0/1 1 /6 0/2
Piura et al. [46]1 / 2 0/1
1DOC
0/3
1DOC
1/1 0/1 0/2
Thomas et al. [41] 0/11 0/3 0/1
Elit et al.∗ 0/3 0/4 1/1 0/2 0/1 1/1 0/1 0/5 0/3
Total 8/64 8/19 4/9 3/13 1/29 7/16 0/10 2/20 2/8 3/42 9/65 5/21
Percent 12.5% 42% 44% 23% 3% 43.7% 0 10% 25% 7% 14% 25%
Stage 1A 12.5% 23% 0 7%
Stage 1B 42% 3% 10% 14%
Stage 1C 44% 43.7% 25% 25%
∗Data from Elit are not added to summary statistics as median followup is less than 24 months.ISRN Obstetrics and Gynecology 7
Table 6: Outcomes report by study.
Author 5yr OS 5yr PFS Other 1A 1B 1C
Bristow et al.
[28] 82%
Carcangiu et al.
[33] 83%
Dietrich et al.
[34]
85.7% platinum +
cyclo or platinum
alone100% for carbo
+t a x o l
Fields et al. [32] 3yr OS 75%
3yr DFS 69%
Grice et al. [43] 84% 48mos 
Huh et al. [29] 72% 70%
Havrilesky et al.
[39]
Rads only
3yr OS 63%
3yr PFS 44%
3yr OS 95%,
PFS 85%
3yr OS 69%,
PFS 59%
3yr OS 79%,
PFS 60%
Kelly et al. [40]5 1 m o s   37mos  44mos 
Low et al. [45] 73%
Piura et al. [46]
83.3% 3yr for 10
patients only 7
surgically staged
34mos  46mos  35mos 
Slomovitz et al.
[47] 63% 5yr OS 81.5% 5yr OS 58.6% 5yr OS 34.3%
Thomas et al.
[41] 85% 78% 5yr OS 100% 5yr OS 89% 5yr OS 60%
5yrOS.
DFS: disease free survival.
 : Median survival.
1B and 1C. In earlier reports, management results grouped
UPSC with other high-grade cancers like clear cell; thus,
it was diﬃcult to discern the outcome of the UPSC cases
and likely those cases were excluded. Many earlier studies
reported on all stages of UPSC or a combination of Stages
1 and 2 versus focusing in on just Stage 1. Again, the
information from these studies was likely excluded. The
quality of the surgical staging varied across studies, that
is, retroperitoneal node dissection only versus addition of
omentectomy and peritoneal biopsies. Many earlier studies
report their “experience with UPSC” and describe several
adjuvant treatment strategies with small number of cases in
each strata. Bias in choosing a managementstrategy is clearly
an issue here. The radiation techniques varied across studies.
Follow-up time in some studies was short, that is, 3 years;
however, most recurrences were noted within the ﬁrst 2 years
after treatment, thus the impact of this short follow-up is not
as concerning as may be the case in other disease types.
A randomized study provides the best opportunity for
deﬁning management. However, given the limitations listed
about a randomized study in this rare entity is unlikely. This
study of the current literature does provide themes around
improvements for care in women with Stage 1 UPSC. There
appears to be a role for chemotherapy in preventing the high
rate of distant disease. There appears to be a role for some
form of radiation, either vault brachytherapy or whole pelvic
radiation to decrease the high risk of vault relapses.
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